Effectiveness of a Health Education Programme for Prevention of Chronic Migraine: A Randomized Clinical Trial

Design: A randomised, double-blind, controlled clinical trial will be conducted in two parallel groups, in which all patients with migraine chronic are receiving prophylactic drug treatment with Fremanezumab or Erenumab as prescribed by a physician. Moreover, patients in the experimental group will receive a health education programme and patients in the control group will receive a programme of general recommendations. Intervention: A 4-week baseline data collection period is included to record the frequency and intensity of migraine pain before starting the study. The intervention will be carried out for 6 months with a follow-up at 1, 3 and 12 months. Experimental group: Patients will receive health education through video-tutorials that can be watched on the HEFORA platform. Each video-tutorial will contain the content of an educational session, including health information in the areas of pain education, migraine neurophysiology, relaxation techniques, sleep habits, eating habits, physical exercise, coping strategies and emotion management. Control group: Patients will receive video-tutorials with general recommendations though HEFORA platform.